# Wolverine legal status, FDA 503A category, and compounding access — BPC-157 TB-500 > Wolverine legal status: both BPC-157 TB-500 components sit in FDA's 503A Category 2 (significant-safety-risk bulk substances) since the September 29, 2023 list update. Access is under active FDA review, with a PCAC meeting scheduled July 23-24, 2026. Both of the BPC-157 TB-500 blend's components are research peptides that the FDA currently places in 503A "Category 2" — bulk substances identified as possibly presenting significant safety risks — which restricts compounding-pharmacy access today. But the file is moving: access is under active FDA review and may expand in 2026, anchored on a scheduled Pharmacy Compounding Advisory Committee meeting where both peptides are on the agenda. ## The forward-leaning headline: access is under active FDA review The most important thing about the Wolverine legal status right now is that it is in motion. Both components of the BPC-157 TB-500 blend are under active FDA review for compounding access, and that access may expand in 2026. The concrete, citable anchor for that momentum is a scheduled event: the FDA's Pharmacy Compounding Advisory Committee (PCAC) is set to meet on July 23-24, 2026 to discuss BPC-157 and TB-500, among other peptides, as bulk drug substances "being considered for inclusion on the 503A Bulks List" [13]. Read that precisely. A PCAC meeting is a scheduled discussion of substances under evaluation. It is advisory, not a decision; inclusion on a final bulks list is decided by FDA rulemaking, and a committee discussion is one step in that evaluation, not its outcome [14]. No reclassification has occurred, none is dated, and none is certain. What is true today is that the question is open and on the FDA's calendar — which is a meaningfully different posture from a closed door. This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance. ## The current fact: both components are in FDA 503A Category 2 As of today, the present-tense regulatory fact is restrictive. Drug compounding in the U.S. is governed by two sections of the Federal Food, Drug, and Cosmetic Act: Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians; Section 503B covers FDA-registered outsourcing facilities compounding in larger volumes [14]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [14]. Neither BPC-157 nor TB-500 meets that bar today. The FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [12]. In the same update, the FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in Category 2, citing potential immunogenicity for certain routes and a lack of important safety information; the FDA's own list entry establishes that TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 [12]. Category 2 matters because of what it withholds: per FDA's interim policy, Category 2 substances are those nominated with sufficient information to evaluate but identified as raising significant safety risks, and they are not covered by the enforcement-discretion policy that applies to Category 1 — the FDA stated it would consider taking action against a compounder who compounds with a Category 2 substance [12]. So compounding-pharmacy access to both BPC-157 and TB-500 is currently restricted. Neither is an FDA-approved drug, and the assembled blend has no approved therapeutic indication. ## No component carve-out: both peptides are on the July 2026 PCAC agenda There is no split decision available here. Both of Wolverine's components — BPC-157 and TB-500, the thymosin beta-4 fragment LKKTETQ — are currently in Category 2, and both are named on the published agenda of the same scheduled review [12][13]. The FDA's public calendar lists BPC-157 (as "BPC-157 (free base)" / "BPC-157 acetate") and TB-500 (as "TB-500 (free base)" / "TB-500 acetate") among the bulk drug substances being considered for inclusion on the 503A bulks list at the July 23-24, 2026 PCAC meeting [13]. Neither peptide has a separate, more permissive status; neither is carved out of the current restriction or the upcoming review. They entered Category 2 together in 2023 [12], and they are under the same scheduled evaluation in 2026 [13]. Whatever the committee discusses, it discusses for both. And again — that discussion is an evaluation step, not a listing, a reclassification, or a dated outcome [14]. ## How legally compounded peptide access works In general terms, lawful access to a compounded medication in the U.S. follows a defined pathway, and it is worth understanding before any specific substance enters the picture [14]. First, an individual patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. Telehealth functions here as a front-end channel to that prescriber consultation; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription [14]. Second, if appropriate and lawful, the prescriber issues a valid, patient-specific prescription. Third, that prescription is dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [14]. The caveat sits on top of all three steps: the compounder may use the requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. An ingredient the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [14]. For BPC-157 and TB-500, that is the current state — which is exactly why their place on the July 2026 review agenda is the part of the file worth watching [13]. This is a description of how the framework works in general; it names no pharmacy, clinic, telehealth provider, or vendor, and it is not guidance on obtaining any substance. ## Access and regulatory questions --- A hand-drawn lab notebook on the BPC-157 TB-500 blend — each component study inked from its source and the missing combination trial circled in the margin in red, with no clinic behind the page and nothing here dispensed or sold.